Preclinical studies identifying carboplatin as a viable cisplatin alternative.
The claims of eight cisplatin analogues as viable alternatives to the parent drug are discussed in terms of their toxicities, antitumour properties and potential biochemical selectivities. It is concluded that, of the eight, diammine (1,1-cyclobutane dicarboxylato)platinum(II) (carboplatin, CBDCA, JM8) had the features most desirable to merit its clinical evaluation.
D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D001769:Blood / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D016190:Carboplatin; D002945:Cisplatin / Q000627:therapeutic use / Q000633:toxicity*; D004353:Drug Evaluation, Preclinical; D007668:Kidney / Q000187:drug effects; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009698:Nucleoproteins / Q000378:metabolism; D009944:Organoplatinum Compounds / Q000627:therapeutic use / Q000633:toxicity*; D010766:Phosphorylation; D051381:Rats; D011919:Rats, Inbred Strains; D013329:Structure-Activity Relationship; D014508:Urea / Q000097:blood
D000970:Antineoplastic Agents; D009698:Nucleoproteins; D009944:Organoplatinum Compounds; D014508:Urea; D016190:Carboplatin; D002945:Cisplatin